IndustryCompany release

Praxis Precision Medicines sets peak sales view above $20bn at New York Investor Day

🇺🇸 Praxis Precision Medicines, Inc. (PRAX) · Thu 12 Nov 2026

The US neurology company named four late-stage assets and said it is building commercial readiness across epilepsy, movement disorders, neurodevelopment and pain.

Praxis Precision Medicines used its Investor Day in New York City on 12 November 2026 to set out its plan to become a leading neurology company. It gave peak sales guidance of more than $20bn.

The company highlighted four late-stage assets. Ulixacaltamide is aimed at essential tremor. Relutrigine targets developmental and epileptic encephalopathies (DEE) linked to SCN2A and SCN8A. Vormatrigine is being developed for focal onset seizures. Elsunersen is aimed at early-onset SCN2A DEE.

Praxis also emphasised commercial readiness and a broader pipeline spanning epilepsy, movement disorders, neurodevelopment and pain. The material available to VigiEye was a summary only, so details such as development timelines, trial data and the assumptions behind the sales view are not covered here.

What it means for your team

  • Market-access teams in neurology and rare epilepsy may wish to watch Praxis's commercial preparations, given its stated focus on readiness.
  • Relutrigine and elsunersen both target SCN2A-related DEE, so the company's activity in this rare-disease area is worth tracking.
  • The $20bn-plus peak sales figure is company guidance, not a regulatory or payer assessment. Detailed assumptions were not available in the summary reviewed.

Company's press release (SEC filing): Praxis Precision Medicines, Inc. ↗

Article written by VigiEye from the official source (Praxis Precision Medicines, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →